NEW YORK, May 2, 2013 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company") today announced it will present the results of two in vitro studies investigating the antimicrobial properties of the Company's SilverSeal® hydrogel dressing. Data from these studies indicate that SilverSeal may be capable of rapid and sustained efficacy in managing the occurrence of wound contamination by reducing the bioburden from multiple bacterial pathogens and by sustaining this activity for up to eight days. Complete data will be presented at the Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting taking place May 1-5, 2013 in Denver, CO.

The first study tested the bactericidal activity of SilverSeal against pathogens commonly associated with wound infections, including MRSA and VRE. SilverSeal dressings were exposed for up to 24 hours to methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae. Concentrations of E. coli, P. aeruginosa, MRSA, E. faecalis and K. pneumoniae had been reduced by >99.99%; and of VRE after 24 hours.

"The ability of SilverSeal to control these bacterial pathogens is a very important finding in today's environment where health officials around the globe are voicing concern over the rising prevalence of resistant hospital-acquired infections, including surgical site infections," stated David Johnson, Alliqua's chief executive officer. "The timing of these findings is particularly opportune as we institute plans to increase our marketing of these dressing solutions through our growing sales organization to the acute care and post-acute care marketplace."

The second study measured the time during which silver ions are released from SilverSeal dressings in concentrations sufficient to provide antimicrobial activity. These findings indicate that SilverSeal delivers a sufficient, sustained concentration of silver ions to provide antimicrobial activity for up to eight days in both water and normal saline in vitro and supports a seven-day dressing change period.

The above results are summarized in two posters, both of which will be on exhibit May 2-4 in the Korbel Ballroom: "Silver Ion Release from a Silver Fiber Hydrogel Wound Dressing" (abstract #LB-27), and "Bactericidal Activity of a Silver-coated Nylon Fiber Hydrogel Wound Dressing" (abstract #LB-45).

Alliqua currently markets its new line of 510K FDA-approved hydrogel products for wound care under the SilverSeal® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises. Additionally, our subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on April 16, 2013 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.